RTP Mobile Logo
Hematologic Oncology Update, Issue 2, 2016 (Video Program)
Released December 2016

Proceedings from video interviews with Drs Philippe Armand, Jonathan W Friedberg, Hagop M Kantarjian and S Vincent Rajkumar on the treatment of hematologic cancers.

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists and other healthcare providers involved in the treatment of hematologic cancers.

    The term hematologic cancer is applicable to any neoplasm originating in the blood, lymph or marrow, but the unique clinical characteristics and treatment considerations of the many individual diseases culminating from this single body system necessitate the further subdivision of these disorders by common etiologic pathway. As such, hematologic cancers include the lymphomas, the leukemias, multiple myeloma and other related disorders such as myelodysplastic syndrome and myeloproliferative diseases stemming from lymphoid and myeloid progenitor cell lines. Taken together, it is estimated that 171,550 new lymphoid, myeloid and leukemic cancer cases will be identified in the United States in the year 2016 and 58,320 individuals will die from these diseases.

    The treatment of hematologic cancer remains a challenge for many healthcare professionals and patients despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    • Consider available clinical research reports on the formulation of therapeutic recommendations for patients with newly diagnosed follicular lymphoma.
    • Appreciate the FDA approvals of novel targeted agents — ibrutinib, obinutuzumab and venetoclax — for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and discern how these therapies can be appropriately integrated into the clinical management of standard- and high-risk disease.
    • Recognize the recent FDA approvals of daratumumab, elotuzumab, ixazomib and panobinostat, and effectively identify where and how these agents should be integrated into the clinical management of relapsed or refractory multiple myeloma.
    • Review emerging clinical trial data on the efficacy and safety of brentuximab vedotin for patients with CD30-positive lymphomas, and use this information to prioritize protocol and nonresearch options for these patients.
    • Incorporate new therapeutic strategies into the best-practice management of newly diagnosed and relapsed/refractory Hodgkin lymphoma.
    • Assess the benefits of ongoing clinical trials for patients with hematologic cancers, and inform appropriately selected patients about these options for treatment.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Philippe Armand, MD, PhD
    Harold and Virginia Lash Chair in Lymphoma Research
    Department of Medical Oncology, Dana-Farber Cancer Institute
    Associate Professor of Medicine, Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: Bristol-Myers Squibb Company, Merck.

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Consulting Agreement and Data and Safety Monitoring Board: Bayer HealthCare Pharmaceuticals.

    Hagop M Kantarjian, MD
    Chairman and Professor, Leukemia Department
    The University of Texas MD Anderson Cancer Center
    Houston, Texas

    Contracted Research: Amgen Inc, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation.

    S Vincent Rajkumar, MD
    Edward W and Betty Knight Scripps Professor of Medicine
    Division of Hematology
    Chair, Myeloma Amyloidosis Dysproteinemia Group
    Mayo Clinic
    Rochester, Minnesota

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc. 

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2016
    Expiration date: December 2017

Acknowledge and close

Watch video
(WIFI is recommended for best performance):
Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia — Dr Friedberg
  • Phase III GALLIUM trial: Progression-free survival benefit with obinutuzumab and chemotherapy compared to rituximab and chemotherapy followed by obinutuzumab or rituximab maintenance for previously untreated follicular lymphoma (FL)
  • Phase II ECOG-E2408 trial: Bendamustine/rituximab (BR) with or without bortezomib for previously untreated high-risk FL
  • Incorporation of the newly FDA-approved Bcl-2 inhibitor venetoclax into the treatment of chronic lymphocytic leukemia (CLL)
  • Bruton tyrosine kinase inhibitors (TKIs) ibrutinib and acalabrutinib (ACP-196) in CLL
  • Evolving treatment options for younger and older patients with CLL
  • CD30 testing in T-cell lymphomas
  • Investigation of lenalidomide in primary CNS lymphoma
Acute Leukemias, Chronic Myeloid Leukemia, Myelodysplastic Syndromes and Myeloproliferative Neoplasms — Dr Kantarjian
  • Novel agents under investigation for FLT3-mutated acute myeloid leukemia (AML)
  • Trials of venetoclax alone or in combination with hypomethylating agents in AML and myelodysplastic syndromes (MDS)
  • New directions in the management of MDS
  • Use of hypomethylating agents in MDS
  • Bispecific T-cell engager blinatumomab in Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (ALL)
  • Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory ALL
  • Immune checkpoint inhibitors in acute leukemias
  • Discontinuing TKIs in responding patients with chronic myeloid leukemia (CML)
  • Ruxolitinib in myelofibrosis and polycythemia vera
Multiple Myeloma — Dr Rajkumar
  • Optimal induction regimen for multiple myeloma (MM)
  • Minimal residual disease measurement in MM
  • Current role of transplant in MM
  • Management approach for patients with disease progression on lenalidomide maintenance
  • Therapeutic options for patients with MM refractory or intolerant to multiple maintenance therapies
  • Proteasome inhibitors as part of post-transplant maintenance, including ixazomib
  • Gastrointestinal toxicity with ixazomib
  • Once-weekly carfilzomib
  • Phase III studies of daratumumab with either lenalidomide/dexamethasone (POLLUX) or bortezomib/dexamethasone (CASTOR) for patients with MM
  • Single-agent activity of daratumumab
  • Daratumumab-associated infusion reactions
  • Utility of panobinostat in combination with proteasome inhibitors
  • Management of Waldenström macroglobulinemia
Hodgkin Lymphoma — Dr Armand
  • Biology of immune checkpoint inhibitors in Hodgkin lymphoma (HL)
  • Early trial data with nivolumab and pembrolizumab in HL
  • Integration of nivolumab into HL management
  • Tolerability of immune checkpoint inhibitors in patients with HL
  • PD-L1 blockade in HL
  • Allotransplant for patients responding to an immune checkpoint inhibitor
  • Efficacy of immune checkpoint inhibitors after allogeneic transplantation
  • Spectrum of cancers responding to immune checkpoint inhibitors
  • Integration of brentuximab vedotin in HL management
  • Brentuximab vedotin-associated peripheral neuropathy
  • Management of HL in elderly patients